[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 23 of about 23
1. Watanabe T, Kato H, Kobayashi Y, Yamasaki S, Morita-Hoshi Y, Yokoyama H, Morishima Y, Ricker JL, Otsuki T, Miyagi-Maesima A, Matsuno Y, Tobinai K: Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma. Cancer Sci; 2010 Jan;101(1):196-200
Hazardous Substances Data Bank. Vorinostat .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma.
  • Vorinostat (suberoylanilide hydroxamic acid, SAHA, Zolinza) is a histone deacetylase inhibitor with clinical activity in cutaneous T-cell lymphoma (CTCL).
  • A phase I trial of oral vorinostat was conducted in Japanese patients with malignant lymphoma.
  • Of 10 patients enrolled, four had follicular lymphoma (FL), two mantle cell lymphoma (MCL), two diffuse large B-cell lymphoma, and two CTCL (median age, 60 years; median number of prior regimens, 3).
  • The median number of treatment cycles was five (range, 1-36); two patients were continuing treatment.
  • The median time to achieve CRu among the three patients was 8 months.
  • These data suggest that further investigations of vorinostat in non-Hodgkin lymphoma, focusing on FL and MCL, are warranted.
  • [MeSH-major] Histone Deacetylase Inhibitors / therapeutic use. Hydroxamic Acids / therapeutic use. Lymphoma, Follicular / drug therapy. Lymphoma, Mantle-Cell / drug therapy

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19817748.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00127140
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Histone Deacetylase Inhibitors; 0 / Hydroxamic Acids; 58IFB293JI / vorinostat
  •  go-up   go-down


2. Chow L, Lai R, Dabbagh L, Belch A, Young JD, Cass CE, Mackey JR: Analysis of human equilibrative nucleoside transporter 1 (hENT1) protein in non-Hodgkin's lymphoma by immunohistochemistry. Mod Pathol; 2005 Apr;18(4):558-64
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of human equilibrative nucleoside transporter 1 (hENT1) protein in non-Hodgkin's lymphoma by immunohistochemistry.
  • Deficiency in hENT1 confers resistance to toxicity of these drugs in a variety of model systems.
  • Since some nucleoside analogs have a role in treating patients with non-Hodgkin's lymphoma (NHL), this study was undertaken to assess hENT1 abundance in NHL.
  • A total of 115 cases of NHL of various subtypes and 15 reactive lymph nodes were evaluated for the presence of hENT1 protein using immunohistochemistry applied to frozen tissues.
  • In reactive lymph nodes, hENT1 was confined to the germinal centers, whereas mantle zone B-cells and interfollicular T-cells were negative.
  • In NHL, a relatively high frequency of hENT1 positivity was found in Burkitt lymphoma/leukemia (63%), diffuse large B-cell lymphoma (DLCL; 45%), and follicular lymphoma (40%).
  • A lower frequency of hENT1 positivity was found in mantle cell lymphoma (13%) and peripheral T-cell lymphomas (37%).
  • All marginal zone lymphomas (n=5), chronic lymphocytic leukemia small lymphocytic lymphomas (n=10), plasmacytoma (n=3), acute lymphoblastic lymphoma/leukemia, and anaplastic large-cell lymphomas (n=5) were negative.
  • In conclusion, hENT1 was most frequently found in benign and malignant follicular center cells.
  • Prospective studies to assess the value of hENT1 immunostaining in predicting resistance to nucleoside chemotherapy for NHL are warranted.
  • [MeSH-major] Equilibrative Nucleoside Transporter 1 / analysis. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Germinal Center / chemistry. Humans. Immunohistochemistry. Lymph Nodes / chemistry. Neprilysin / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15529184.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Equilibrative Nucleoside Transporter 1; 0 / SLC29A1 protein, human; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


3. Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, Lacasce A, Schaefer-Cutillo J, De Vos S, Sinha R, Leonard JP, Cripe LD, Gregory SA, Sterba MP, Lowe AM, Levy R, Shipp MA: Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood; 2010 Apr 01;115(13):2578-85
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia.
  • Certain malignant B cells rely on B-cell receptor (BCR)-mediated survival signals.
  • In in vivo analyses of B-cell lymphoma cell lines and primary tumors, Syk inhibition induces apoptosis.
  • These data prompted a phase 1/2 clinical trial of fostamatinib disodium, the first clinically available oral Syk inhibitor, in patients with recurrent B-cell non-Hodgkin lymphoma (B-NHL).
  • (1) diffuse large B-cell lymphoma (DLBCL), (2) follicular lymphoma (FL), and (3) other NHL, including mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), mucosa-associated lymphoid tissue lymphoma, lymphoplasmacytic lymphomas, and small lymphocytic leukemia/chronic lymphocytic leukemia (SLL/CLL).
  • Disrupting BCR-induced signaling by inhibiting Syk represents a novel and active therapeutic approach for NHL and SLL/CLL.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Intracellular Signaling Peptides and Proteins / antagonists & inhibitors. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Neoplasm Proteins / antagonists & inhibitors. Oxazines / therapeutic use. Protein Kinase Inhibitors / therapeutic use. Protein-Tyrosine Kinases / antagonists & inhibitors. Pyridines / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cohort Studies. Diarrhea / chemically induced. Disease-Free Survival. Female. Hematologic Diseases / chemically induced. Humans. Hypertension / chemically induced. Male. Middle Aged. Salvage Therapy. Syk Kinase. Treatment Outcome

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2007 Feb 15;356(7):741-2 [17301308.001]
  • [Cites] Leukemia. 2006 Dec;20(12):2093-101 [17051243.001]
  • [Cites] Toxicol Appl Pharmacol. 2007 Jun 15;221(3):268-77 [17490694.001]
  • [Cites] Blood. 2008 Feb 15;111(4):2230-7 [18006696.001]
  • [Cites] Blood. 2008 Aug 1;112(3):782-92 [18487510.001]
  • [Cites] J Clin Oncol. 2008 Oct 1;26(28):4579-86 [18662969.001]
  • [Cites] Arthritis Rheum. 2008 Nov;58(11):3309-18 [18975322.001]
  • [Cites] J Intern Med. 2008 Dec;264(6):549-62 [19017179.001]
  • [Cites] Birth Defects Res A Clin Mol Teratol. 2009 Feb;85(2):130-6 [19107952.001]
  • [Cites] Blood. 2009 Mar 12;113(11):2508-16 [18981293.001]
  • [Cites] Blood. 2009 Mar 26;113(13):3050-8 [19074730.001]
  • [Cites] Blood. 2009 Apr 2;113(14):3154-60 [19096013.001]
  • [Cites] Blood. 2009 Jun 11;113(24):6153-60 [19369227.001]
  • [Cites] Blood. 2009 Jul 16;114(3):638-46 [19387007.001]
  • [Cites] Blood. 2009 Jul 30;114(5):1029-37 [19491390.001]
  • [Cites] J Clin Oncol. 2009 Aug 10;27(23):3822-9 [19581539.001]
  • [Cites] Blood. 2006 Dec 15;108(13):4156-62 [16912221.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] Blood. 2007 Mar 1;109(5):1857-61 [17105812.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):579-86 [17242396.001]
  • [Cites] Immunol Today. 2000 Mar;21(3):148-54 [10689303.001]
  • [Cites] J Immunol. 2000 Aug 1;165(3):1300-6 [10903730.001]
  • [Cites] Science. 2002 May 31;296(5573):1641-2 [12040177.001]
  • [Cites] J Allergy Clin Immunol. 2002 Sep;110(3):366-73 [12209081.001]
  • [Cites] Mol Cell. 2002 Nov;10(5):1057-69 [12453414.001]
  • [Cites] N Engl J Med. 2003 May 1;348(18):1764-75 [12724482.001]
  • [Cites] Cell. 2004 Jun 11;117(6):787-800 [15186779.001]
  • [Cites] Mol Cell. 2004 Jun 18;14(6):696-7 [15200948.001]
  • [Cites] Cell. 1997 Sep 19;90(6):1073-83 [9323135.001]
  • [Cites] Curr Opin Immunol. 1999 Apr;11(2):143-51 [10322153.001]
  • [Cites] Blood. 2005 Mar 1;105(5):1851-61 [15550490.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4117-26 [15867204.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2005;:329-34 [16304399.001]
  • [Cites] Br J Haematol. 2006 Feb;132(3):303-16 [16409295.001]
  • [Cites] Nat Rev Immunol. 2006 Apr;6(4):283-94 [16557260.001]
  • [Cites] J Immunol. 2006 May 15;176(10):5715-9 [16670274.001]
  • [Cites] J Clin Oncol. 2006 Oct 20;24(30):4867-74 [17001068.001]
  • [Cites] Blood. 2006 Nov 1;108(9):3135-42 [16835385.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3428-33 [16888096.001]
  • [Cites] J Pharmacol Exp Ther. 2006 Dec;319(3):998-1008 [16946104.001]
  • [CommentIn] Blood. 2010 Apr 1;115(13):2561-2 [20360472.001]
  • (PMID = 19965662.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00446095
  • [Grant] United States / NCI NIH HHS / CA / P50 CA130805; United States / NCI NIH HHS / CA / CA-130805
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Intracellular Signaling Peptides and Proteins; 0 / Neoplasm Proteins; 0 / Oxazines; 0 / Protein Kinase Inhibitors; 0 / Pyridines; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / SYK protein, human; EC 2.7.10.2 / Syk Kinase; SQ8A3S5101 / fostamatinib
  • [Other-IDs] NLM/ PMC2852362
  •  go-up   go-down


Advertisement
4. Imataki O, Tamai Y, Kawakami K: [Comparison of salvage chemotherapy regimen ACES with ESHAP for refractory or relapsed malignant lymphoma]. Gan To Kagaku Ryoho; 2007 Oct;34(10):1629-32
Hazardous Substances Data Bank. METHYLPREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparison of salvage chemotherapy regimen ACES with ESHAP for refractory or relapsed malignant lymphoma].
  • Standard salvage chemotherapy for refractory or relapsed malignant lymphoma has not been defined.
  • The efficacy and feasibility of the ACES regimen, consisting of carboplatin at 100 mg/m(2) on day 1 to 4, etoposide at 80 mg/m(2) on day 1 to 4, high-dose Ara-C at 2 g/m(2) on day 5 and methylprednisolone at 500 mg/day for 5 days, for refractory or relapsed lymphoma were retrospectively reviewed in comparison with the ESHAP regimen.
  • The subjects were 29 patients, including 7 aggressive follicular lymphomas, 16 large B cell lymphomas and 6 Hodgkin lymphomas.
  • We concluded that the ACES regimen had a possibility of effective consolidation therapy for the elderly aiming to undergo autologous stem cell transplantation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma / drug therapy. Salvage Therapy / methods
  • [MeSH-minor] Adult. Aged. Carboplatin / administration & dosage. Cisplatin / therapeutic use. Cisplatin / toxicity. Cytarabine / administration & dosage. Cytarabine / therapeutic use. Cytarabine / toxicity. Etoposide / administration & dosage. Etoposide / therapeutic use. Etoposide / toxicity. Female. Humans. Male. Methylprednisolone / administration & dosage. Methylprednisolone / therapeutic use. Methylprednisolone / toxicity. Middle Aged. Retrospective Studies. Stem Cell Transplantation

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17940378.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin; X4W7ZR7023 / Methylprednisolone; ESAP protocol
  •  go-up   go-down


5. Jahrsdorfer B, Mühlenhoff L, Blackwell SE, Wagner M, Poeck H, Hartmann E, Jox R, Giese T, Emmerich B, Endres S, Weiner GJ, Hartmann G: B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides. Clin Cancer Res; 2005 Feb 15;11(4):1490-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides.
  • Synthetic CpG oligodeoxynucleotides are currently being tested in clinical trials for the therapy of different types of B cell non-Hodgkin's lymphoma.
  • However, there is only limited information on the CpG oligodeoxynucleotide sensitivity of primary malignant B cells of different non-Hodgkin's lymphoma entities.
  • Here we found that most B-cell malignancies except plasmacytoma respond to CpG oligodeoxynucleotides by up-regulating expression of costimulatory and antigen-presenting molecules, by increasing expression of CD20, and by proliferation.
  • In an in vitro analysis of 41 individual patient-derived primary tumor samples, B-cell chronic lymphocytic leukemia (B-CLL) and marginal zone lymphoma showed the strongest activation upon stimulation with CpG oligodeoxynucleotides.
  • Small lymphocytic lymphoma, follicular lymphoma, mantle cell lymphoma, and large cell lymphoma showed an intermediate response.
  • Although CpG oligodeoxynucleotides induced proliferation in all CpG oligodeoxynucleotide-sensitive types of B-cell malignancies, proliferation was weaker than in normal B cells and at least for B-CLL was followed by increased apoptosis.
  • In conclusion, B-cell malignancies show significant differences in their responsiveness to CpG oligodeoxynucleotides.
  • Focusing clinical studies on patients with highly CpG oligodeoxynucleotide-sensitive B-cell malignancies may improve the clinical outcome of such trials.
  • [MeSH-major] Lymphoma, B-Cell / drug therapy. Oligodeoxyribonucleotides / pharmacology
  • [MeSH-minor] Adjuvants, Immunologic / pharmacology. Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / immunology. Antibodies, Monoclonal, Murine-Derived. Antigens, CD20 / biosynthesis. Antigens, CD20 / immunology. Cell Proliferation / drug effects. Cell Survival / drug effects. Child. Child, Preschool. Female. Gene Expression Regulation, Neoplastic / drug effects. Humans. Male. Membrane Glycoproteins / genetics. Middle Aged. Plasmacytoma / drug therapy. Plasmacytoma / genetics. Plasmacytoma / pathology. RNA, Messenger / genetics. RNA, Messenger / metabolism. Receptors, Cell Surface / genetics. Rituximab. Time Factors. Toll-Like Receptor 9. Toll-Like Receptors. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15746051.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / CPG-oligonucleotide; 0 / Membrane Glycoproteins; 0 / Oligodeoxyribonucleotides; 0 / RNA, Messenger; 0 / Receptors, Cell Surface; 0 / TLR9 protein, human; 0 / Toll-Like Receptor 9; 0 / Toll-Like Receptors; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


6. Staudt LM, Dave S: The biology of human lymphoid malignancies revealed by gene expression profiling. Adv Immunol; 2005;87:163-208
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Diffuse large B-cell lymphoma (DLBCL), for example, consists of three gene expression subgroups, termed germinal center B-cell-like (GCB) DLBCL, activated B-cell-like (ABC) DLBCL, and primary mediastinal B-cell lymphoma (PMBL).
  • These DLBCL subgroups arise from different stages of normal B-cell differentiation, utilize distinct oncogenic mechanisms, and differ in their ability to be cured by chemotherapy.
  • ABC DLBCL and PMBL depend upon constitutive activation of the NF-kappaB pathway for their survival but GCB DLBCL does not, demonstrating that this pathway is a potential therapeutic target for certain DLBCL subgroups.
  • In DLBCL, mantle cell lymphoma, and follicular lymphoma, gene expression profiling has also been used to create gene expression-based models of survival, which have identified the biological characteristics of the tumors that influence their clinical behavior.
  • In mantle cell lymphoma, the length of survival following diagnosis is primarily influenced by the tumor proliferation rate, which can be quantitatively measured by a proliferation gene expression "signature."
  • Based on this accurate measure, the proliferation rate can now be viewed as an integration of several oncogenic lesions that each increase progression from the G1 to the S phase of the cell cycle.
  • In DLBCL and follicular lymphoma, gene expression profiling has revealed that the molecular characteristics of non-malignant tumor-infiltrating immune cells have a major influence on the length of survival.
  • The implications of these insights for the diagnosis and treatment of non-Hodgkin lymphomas are discussed.

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1999 Nov 1;94(9):3129-34 [10556199.001]
  • [Cites] Nat Med. 1999 Dec;5(12):1365-9 [10581077.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Cancer Res. 2000 Feb 1;60(3):549-52 [10676635.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] Ann Oncol. 2000;11 Suppl 1:23-7 [10707774.001]
  • [Cites] Blood. 2000 Mar 15;95(6):2084-92 [10706878.001]
  • [Cites] J Immunol. 2000 Jun 1;164(11):5998-6004 [10820283.001]
  • [Cites] Am J Pathol. 2000 Jun;156(6):1987-96 [10854221.001]
  • [Cites] Genes Dev. 2000 Jul 15;14(14):1810-23 [10898795.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Aug 29;97(18):10209-13 [10954754.001]
  • [Cites] Immunity. 2000 Aug;13(2):199-212 [10981963.001]
  • [Cites] J Exp Med. 2000 Oct 2;192(7):1027-34 [11015443.001]
  • [Cites] Mol Cell Biol. 2000 Nov;20(21):7903-13 [11027261.001]
  • [Cites] J Immunol. 2000 Nov 15;165(10):5462-71 [11067898.001]
  • [Cites] Semin Cancer Biol. 2000 Oct;10(5):331-40 [11100880.001]
  • [Cites] Blood. 2001 Jan 1;97(1):101-6 [11133748.001]
  • [Cites] Blood. 2001 Jan 1;97(1):250-5 [11133768.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 1999;64:71-8 [11232339.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Apr;30(4):393-401 [11241792.001]
  • [Cites] Nat Immunol. 2001 Mar;2(3):261-8 [11224527.001]
  • [Cites] Nat Immunol. 2000 Dec;1(6):526-32 [11101876.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2409-12 [11289106.001]
  • [Cites] Nature. 2001 Apr 26;410(6832):1099-103 [11323673.001]
  • [Cites] Am J Surg Pathol. 2001 Jul;25(7):925-9 [11420464.001]
  • [Cites] Nature. 2001 Jul 19;412(6844):300-7 [11460154.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9654-9 [11481442.001]
  • [Cites] Hum Pathol. 2001 Sep;32(9):926-34 [11567221.001]
  • [Cites] Immunity. 2001 Sep;15(3):375-85 [11567628.001]
  • [Cites] Blood. 2001 Nov 1;98(9):2762-70 [11675349.001]
  • [Cites] J Exp Med. 2001 Dec 17;194(12):1861-74 [11748286.001]
  • [Cites] Nat Med. 2002 Jan;8(1):68-74 [11786909.001]
  • [Cites] Blood. 2002 Mar 1;99(5):1517-26 [11861263.001]
  • [Cites] Immunity. 2002 Jul;17(1):51-62 [12150891.001]
  • [Cites] Nat Med. 2002 Aug;8(8):793-800 [12091876.001]
  • [Cites] Nature. 2002 Aug 22;418(6900):823 [12192390.001]
  • [Cites] Cancer Cell. 2002 Aug;2(2):103-12 [12204530.001]
  • [Cites] Eur J Haematol. 2002 Jul;69(1):11-20 [12270057.001]
  • [Cites] J Mol Med (Berl). 2003 May;81(5):281-7 [12721664.001]
  • [Cites] J Exp Med. 2003 Jun 16;197(12):1721-30 [12810690.001]
  • [Cites] Am J Pathol. 2003 Jul;163(1):135-44 [12819018.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23 [12829800.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9991-6 [12900505.001]
  • [Cites] Semin Cancer Biol. 2003 Jun;13(3):191-202 [12959350.001]
  • [Cites] Am J Surg Pathol. 2003 Sep;27(9):1269-77 [12960812.001]
  • [Cites] J Exp Med. 2003 Sep 15;198(6):851-62 [12975453.001]
  • [Cites] J Biol Chem. 2003 Oct 3;278(40):38980-90 [12860980.001]
  • [Cites] J Clin Pathol. 2003 Oct;56(10):747-52 [14514777.001]
  • [Cites] Genome Biol. 2003;4(10):R69 [14519204.001]
  • [Cites] Immunity. 2003 Oct;19(4):607-20 [14563324.001]
  • [Cites] Nucleic Acids Res. 2003 Nov 1;31(21):6148-56 [14576301.001]
  • [Cites] Blood. 2003 Dec 1;102(12):3871-9 [12933571.001]
  • [Cites] Blood. 2004 Jan 1;103(1):275-82 [14504078.001]
  • [Cites] Cancer Cell. 2004 Feb;5(2):191-9 [14998494.001]
  • [Cites] Nat Rev Cancer. 2004 Apr;4(4):309-14 [15057290.001]
  • [Cites] Am J Surg Pathol. 2004 Apr;28(4):464-70 [15087665.001]
  • [Cites] N Engl J Med. 2004 Apr 29;350(18):1828-37 [15115829.001]
  • [Cites] Blood. 2004 Jun 1;103(11):4251-8 [14976040.001]
  • [Cites] Leuk Lymphoma. 2003;44 Suppl 3:S5-12 [15202519.001]
  • [Cites] Blood. 2004 Jul 15;104(2):543-9 [15044251.001]
  • [Cites] J Immunol. 2004 Jul 15;173(2):1158-65 [15240705.001]
  • [Cites] Cell. 2004 Aug 20;118(4):477-91 [15315760.001]
  • [Cites] J Biol Chem. 2004 Aug 27;279(35):36698-707 [15199070.001]
  • [Cites] Immunity. 2004 Jul;21(1):81-93 [15345222.001]
  • [Cites] Leuk Lymphoma. 2004 Oct;45(10):2105-10 [15370257.001]
  • [Cites] Nature. 2004 Oct 7;431(7009):712-7 [15361884.001]
  • [Cites] Nature. 1982 Sep 2;299(5878):65-7 [7110326.001]
  • [Cites] N Engl J Med. 1984 Dec 6;311(23):1471-5 [6548796.001]
  • [Cites] Histopathology. 1986 Apr;10(4):379-90 [2423430.001]
  • [Cites] Mod Pathol. 2002 Nov;15(11):1172-80 [12429796.001]
  • [Cites] Nat Genet. 2002 Dec;32(4):606-13 [12402037.001]
  • [Cites] Am J Clin Pathol. 1991 Jul;96(1):81-9 [2069139.001]
  • [Cites] Mol Cell Biol. 1991 Oct;11(10):4846-53 [1833629.001]
  • [Cites] Oncogene. 1992 Jul;7(7):1401-6 [1535701.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Aug 1;89(15):6770-4 [1495966.001]
  • [Cites] N Engl J Med. 1992 Oct 22;327(17):1209-15 [1406793.001]
  • [Cites] Am J Surg Pathol. 1992 Sep;16(9):885-95 [1415907.001]
  • [Cites] Immunology. 1992 Dec;77(4):621-3 [1337336.001]
  • [Cites] Leukemia. 1993 Mar;7(3):398-403 [7680400.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] Immunol Res. 1993;12(3):213-32 [8288943.001]
  • [Cites] Blood. 1994 Jun 15;83(12):3689-96 [8204893.001]
  • [Cites] Oncogene. 1994 Jul;9(7):1925-9 [8208539.001]
  • [Cites] Int Immunol. 1994 Aug;6(8):1203-11 [7981148.001]
  • [Cites] Oncogene. 1995 May 4;10(9):1833-40 [7753558.001]
  • [Cites] Blood. 1995 Jul 1;86(1):28-37 [7795234.001]
  • [Cites] Blood. 1995 Jul 1;86(1):45-53 [7795255.001]
  • [Cites] Am J Pathol. 1995 Aug;147(2):405-11 [7639334.001]
  • [Cites] Cell. 1995 Aug 25;82(4):621-30 [7664341.001]
  • [Cites] Biochim Biophys Acta. 1996 Feb 7;1305(1-2):39-43 [8605247.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):8292-7 [9653180.001]
  • [Cites] Mol Cell Biol. 1998 Sep;18(9):5500-10 [9710634.001]
  • [Cites] Oncogene. 1999 Jan 28;18(4):943-53 [10023670.001]
  • [Cites] Oncogene. 1999 May 20;18(20):3063-70 [10340377.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):268-76 [10458242.001]
  • [Cites] Nat Med. 1999 Oct;5(10):1171-7 [10502821.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 1961;26:389-401 [14475415.001]
  • [Cites] N Engl J Med. 2004 Nov 18;351(21):2159-69 [15548776.001]
  • [Cites] Blood. 2005 Nov 1;106(9):3183-90 [16046532.001]
  • [Cites] Biochem Biophys Res Commun. 1996 Mar 27;220(3):911-5 [8607866.001]
  • [Cites] Blood. 1996 Feb 15;87(4):1571-8 [8608249.001]
  • [Cites] J Exp Med. 1996 Feb 1;183(2):393-401 [8627152.001]
  • [Cites] Blood. 1996 May 15;87(10):4340-7 [8639794.001]
  • [Cites] J Exp Med. 1996 Mar 1;183(3):971-7 [8642300.001]
  • [Cites] Oncogene. 1996 Jun 6;12(11):2331-42 [8649773.001]
  • [Cites] J Clin Oncol. 1996 Apr;14(4):1269-74 [8648383.001]
  • [Cites] Blood. 1996 Jun 15;87(12):5257-68 [8652841.001]
  • [Cites] J Immunol. 1996 Jul 1;157(1):81-6 [8683159.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jul 9;93(14):6947-52 [8692924.001]
  • [Cites] Blood. 1996 Aug 15;88(4):1359-64 [8695854.001]
  • [Cites] J Exp Med. 1996 Aug 1;184(2):627-37 [8760816.001]
  • [Cites] J Biol Chem. 1996 Aug 23;271(34):20231-4 [8702752.001]
  • [Cites] Blood. 1997 Jan 1;89(1):272-80 [8978301.001]
  • [Cites] Blood. 1997 Mar 15;89(6):2067-78 [9058729.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Mar 18;94(6):2507-12 [9122225.001]
  • [Cites] Int Immunol. 1997 Mar;9(3):407-14 [9088979.001]
  • [Cites] Science. 1997 Apr 25;276(5312):589-92 [9110977.001]
  • [Cites] Science. 1997 Apr 25;276(5312):596-9 [9110979.001]
  • [Cites] Nat Genet. 1997 Jun;16(2):161-70 [9171827.001]
  • [Cites] Eur J Immunol. 1997 Jun;27(6):1398-405 [9209491.001]
  • [Cites] Blood. 1997 Sep 15;90(6):2188-95 [9310469.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10762-7 [9380707.001]
  • [Cites] Cancer Res. 1997 Oct 15;57(20):4608-14 [9377576.001]
  • [Cites] J Clin Invest. 1997 Dec 15;100(12):2961-9 [9399941.001]
  • [Cites] Cancer. 1998 Feb 1;82(3):567-75 [9452276.001]
  • [Cites] Blood. 1998 Apr 15;91(8):2977-84 [9531609.001]
  • [Cites] Oncogene. 1998 Apr 23;16(16):2131-9 [9572494.001]
  • [Cites] Nucleic Acids Res. 1998 Jun 15;26(12):2899-907 [9611234.001]
  • [Cites] Genes Dev. 1998 Jul 1;12(13):1953-61 [9649500.001]
  • [Cites] Mol Cell Biol. 2002 Mar;22(6):1804-18 [11865059.001]
  • [Cites] Blood. 2002 Apr 1;99(7):2285-90 [11895757.001]
  • [Cites] Blood. 2002 Apr 1;99(7):2562-8 [11895794.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Apr 30;99(9):5757-9 [11983876.001]
  • [Cites] J Clin Oncol. 2002 May 15;20(10):2453-63 [12011122.001]
  • [Cites] Curr Opin Hematol. 2002 Jul;9(4):333-8 [12042708.001]
  • [Cites] Mol Cell Biol. 2002 Jul;22(13):4771-80 [12052884.001]
  • [Cites] N Engl J Med. 2002 Jun 20;346(25):1937-47 [12075054.001]
  • [Cites] Nat Immunol. 2002 Jul;3(7):611-8 [12087419.001]
  • [Cites] Nat Rev Immunol. 2002 Dec;2(12):920-32 [12461565.001]
  • [Cites] Genes Dev. 2002 Dec 1;16(23):2991-3003 [12464630.001]
  • [Cites] Am J Pathol. 2003 Jan;162(1):243-53 [12507907.001]
  • [Cites] Blood. 2003 Jan 15;101(2):433-40 [12509382.001]
  • [Cites] J Biol Chem. 2003 Feb 14;278(7):5205-13 [12435740.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2639-44 [12604779.001]
  • [Cites] Cancer Cell. 2003 Feb;3(2):185-97 [12620412.001]
  • [Cites] J Biol Chem. 2003 Apr 4;278(14):12563-73 [12529326.001]
  • [Cites] Blood. 2003 Apr 15;101(8):3181-7 [12515730.001]
  • [Cites] Cell. 2003 Apr 18;113(2):207-19 [12705869.001]
  • [Cites] Biochem Biophys Res Commun. 2003 May 2;304(2):393-8 [12711328.001]
  • [Cites] N Engl J Med. 2003 May 1;348(18):1777-85 [12724484.001]
  • [Cites] Nat Med. 2003 May;9(5):562-7 [12704383.001]
  • [Cites] Blood. 2003 Jun 1;101(11):4464-71 [12531790.001]
  • (PMID = 16102574.001).
  • [ISSN] 0065-2776
  • [Journal-full-title] Advances in immunology
  • [ISO-abbreviation] Adv. Immunol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / SC / Z01 SC004024-18
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 165
  • [Other-IDs] NLM/ NIHMS5150; NLM/ PMC1351148
  •  go-up   go-down


7. Kitada S, Kress CL, Krajewska M, Jia L, Pellecchia M, Reed JC: Bcl-2 antagonist apogossypol (NSC736630) displays single-agent activity in Bcl-2-transgenic mice and has superior efficacy with less toxicity compared with gossypol (NSC19048). Blood; 2008 Mar 15;111(6):3211-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Altered expression of Bcl-2 family proteins plays central roles in apoptosis dysregulation in cancer and leukemia, promoting malignant cell expansion and contributing to chemoresistance.
  • Daily oral dosing studies showed that mice tolerate doses of apogossypol 2- to 4-times higher than gossypol.
  • Efficacy was tested in transgenic mice in which Bcl-2 is overexpressed in B cells, resembling low-grade follicular lymphoma in humans.
  • In vivo, using the maximum tolerated dose of gossypol for sequential daily dosing, apogossypol displayed superior activity to gossypol in terms of reducing splenomegaly and reducing B-cell counts in spleens of Bcl-2-transgenic mice.
  • Taken together, these studies indicate that apogossypol is superior to parent compound gossypol with respect to toxicology and efficacy, suggesting that further development of this compound for cancer therapy is warranted.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Gossypol .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 2000 Nov 1;165(9):5084-96 [11046039.001]
  • [Cites] Cancer Chemother Pharmacol. 2008 Jan;61(1):63-73 [17356822.001]
  • [Cites] Oncogene. 2003 Nov 24;22(53):8590-607 [14634621.001]
  • [Cites] Cancer Cell. 2004 Jan;5(1):25-35 [14749124.001]
  • [Cites] Chem Biol. 2004 Mar;11(3):389-95 [15123268.001]
  • [Cites] J Immunol. 1982 Aug;129(2):570-5 [6806374.001]
  • [Cites] Blood. 1988 Aug;72(2):679-84 [3401595.001]
  • [Cites] Cancer Res. 1990 Oct 15;50(20):6565-70 [2208117.001]
  • [Cites] Cancer Res. 1992 Jan 15;52(2):491-5 [1728422.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Dec 1;89(23):11376-80 [1454823.001]
  • [Cites] Blood. 1993 Jun 1;81(11):3091-6 [7684624.001]
  • [Cites] Ann Oncol. 1994;5 Suppl 1:61-5 [8172820.001]
  • [Cites] Leukemia. 1994 Oct;8(10):1640-5 [7523797.001]
  • [Cites] Toxicol Lett. 1995 Dec;82-83:155-8 [8597045.001]
  • [Cites] Cancer Treat Res. 1996;84:31-72 [8724625.001]
  • [Cites] J Neurochem. 1998 Aug;71(2):741-8 [9681465.001]
  • [Cites] Clin Cancer Res. 1999 Jul;5(7):1758-66 [10430080.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):9136-41 [10430908.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Nov 23;101(47):16600-5 [15545599.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13944-9 [16166262.001]
  • [Cites] Pharmacogenomics. 2006 Apr;7(3):271-9 [16610939.001]
  • [Cites] J Med Chem. 2006 Jul 13;49(14):4356-66 [16821795.001]
  • [Cites] Cell Death Differ. 2006 Aug;13(8):1419-21 [16645636.001]
  • [Cites] Oncogene. 2006 Oct 9;25(46):6202-10 [17028600.001]
  • [Cites] Nat Rev Cancer. 2006 Nov;6(11):857-66 [17060945.001]
  • [Cites] J Pharm Biomed Anal. 2006 Nov 16;42(5):581-6 [16859853.001]
  • [Cites] Cancer Cell. 2006 Nov;10(5):375-88 [17097560.001]
  • [Cites] J Clin Oncol. 2007 Mar 20;25(9):1114-20 [17296974.001]
  • [Cites] J Appl Toxicol. 2001 Dec;21 Suppl 1:S23-6 [11920916.001]
  • (PMID = 18202226.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CM / N01-CM-52205; United States / NCI NIH HHS / CM / N01-CM-07110; United States / NCI NIH HHS / CA / U19 CA113318; United States / NCI NIH HHS / CA / P01 CA081534; United States / NCI NIH HHS / CA / P01-CA081534; United States / NCI NIH HHS / CA / CA-113318; United States / NCI NIH HHS / CA / N01CM52205
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-bcl-2; 0 / apogossypol; KAV15B369O / Gossypol
  • [Other-IDs] NLM/ PMC2265458
  •  go-up   go-down


8. Blumenfeld Z: Gender difference: fertility preservation in young women but not in men exposed to gonadotoxic chemotherapy. Minerva Endocrinol; 2007 Mar;32(1):23-34
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gender difference: fertility preservation in young women but not in men exposed to gonadotoxic chemotherapy.
  • Decreased secretion of pituitary gonadotropins, by decreasing gonadal function, may possibly protect against the sterilizing effects of chemotherapy.
  • Although previous claims that primordial germ cells fare better than germ cells that are part of an active cell cycle have been made, this hypothesis has not been seriously tested clinically until recently.
  • We have administered a monthly depot i.m. injection of GnRH-a to more than 125 young patients exposed to gonadotoxic chemotherapy for malignant or nonmalignant diseases, after informed consent, starting before chemotherapy for up to 6 months, in parallel and until the end of chemotherapeutic treatment.
  • Less than 7% developed irreversible hypergonadotropic amenorrhea.
  • The remainder (>93%) resumed cyclic ovarian function, of which 32 patients spontaneously conceived 46 times.
  • These patients were compared to a control group of over 125 patients of comparable age (15-40 years), who were similarly treated with chemotherapy but without the GnRH-a adjuvant.
  • The 2 groups were similar in age, diagnosis, and the ratio of HD to non-Hodgkin lymphoma patients.
  • The 2 groups also received similar doses of radiotherapy exposure and the proportion of radio-plus chemotherapy-treated patients was similar.
  • Possible explanations for the beneficial effect of the GnRH-a on minimizing the gonadotoxic effect of chemotherapy are discussed.
  • Multi-center prospective, randomized studies are awaited to substantiate the in vivo effect of GnRH-a as an unequivocal means of minimizing follicular apoptosis.
  • [MeSH-minor] Adolescent. Adult. Animals. Autoimmune Diseases / drug therapy. Azoospermia / chemically induced. Azoospermia / etiology. Clinical Trials as Topic. Cohort Studies. Combined Modality Therapy. Cyclophosphamide / adverse effects. Cyclophosphamide / therapeutic use. Embryo Transfer. Female. Fertilization in Vitro. Germ Cells / drug effects. Germ Cells / radiation effects. Hematologic Neoplasms / complications. Hematologic Neoplasms / drug therapy. Hematologic Neoplasms / radiotherapy. Hodgkin Disease / complications. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy. Humans. Lymphoma, Non-Hodgkin / complications. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / radiotherapy. Macaca mulatta. Male. Mice. Ovary / physiopathology. Pregnancy. Pregnancy Outcome. Primary Ovarian Insufficiency / chemically induced. Primary Ovarian Insufficiency / prevention & control. Primary Ovarian Insufficiency / radiotherapy. Radiotherapy / adverse effects. Triptorelin Pamoate / administration & dosage. Triptorelin Pamoate / pharmacology. Triptorelin Pamoate / therapeutic use

  • MedlinePlus Health Information. consumer health - Female Infertility.
  • MedlinePlus Health Information. consumer health - Male Infertility.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17353864.001).
  • [ISSN] 0391-1977
  • [Journal-full-title] Minerva endocrinologica
  • [ISO-abbreviation] Minerva Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 33515-09-2 / Gonadotropin-Releasing Hormone; 57773-63-4 / Triptorelin Pamoate; 8N3DW7272P / Cyclophosphamide
  • [Number-of-references] 77
  •  go-up   go-down


9. Aurora V, Winter JN: Follicular lymphoma: today's treatments and tomorrow's targets. Expert Opin Pharmacother; 2006 Jul;7(10):1273-90
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Follicular lymphoma: today's treatments and tomorrow's targets.
  • Over the past two decades, the incidence of follicular lymphoma has increased.
  • Contemporary treatments include combinations of chemotherapy and monoclonal antibodies, radioimmunotherapy, new targeted agents and stem-cell transplantation.
  • Prognostic tools are becoming more important in helping clinicians and patients decide on the most appropriate therapeutic regimens.
  • When patients do require therapy, the addition of rituximab to chemotherapy seems to improve remission duration and may improve overall survival.
  • Radioimmunotherapy capitalises on the capacity to target radiation directly to malignant cells, and is currently approved for the treatment of relapsed/refractory follicular lymphoma.
  • Further investigation is needed to clarify the role of stem-cell transplantation in follicular lymphoma.
  • Only well-designed clinical trials can provide answers to the many questions that remain regarding the optimal treatment and sequence of treatments for patients with follicular lymphoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cancer Vaccines / therapeutic use. Hematopoietic Stem Cell Transplantation. Immunologic Factors / therapeutic use. Lymphoma, Follicular / therapy. Radioimmunotherapy
  • [MeSH-minor] Alkylating Agents / therapeutic use. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Combined Modality Therapy. Humans. Interferons / therapeutic use. Patient Selection. Prognosis. Randomized Controlled Trials as Topic. Rituximab

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16805715.001).
  • [ISSN] 1744-7666
  • [Journal-full-title] Expert opinion on pharmacotherapy
  • [ISO-abbreviation] Expert Opin Pharmacother
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Alkylating Agents; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / Cancer Vaccines; 0 / Immunologic Factors; 4F4X42SYQ6 / Rituximab; 9008-11-1 / Interferons
  • [Number-of-references] 115
  •  go-up   go-down


10. Ogura M: [Recent progress in the treatment of malignant lymphoma]. Gan To Kagaku Ryoho; 2001 Sep;28(9):1213-35
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Recent progress in the treatment of malignant lymphoma].
  • The present state of the art and developments in the treatment for Hodgkin's disease (HD), follicular lymphoma (FL), MALT lymphoma, and aggressive non-Hodgkin's lymphoma are reviewed.
  • Four courses of ABVD therapy (ABVd therapy in Japan) followed by involved-field irradiation (IFRT), and 6 to 8 courses of ABVD (ABVd in Japan) are the current state art of the therapy for early stage HD and advanced stage HD, respectively.
  • High-dose chemotherapy with autologous hematopoietic stem cell transplantation (auto-HSCT) is also the state of the art for refractory or relapsed HD within 1 year after complete remission (CR) produced by polychemotherapy.
  • There is no state of the art therapy for indolent lymphoma including FL, or MALT.
  • Promising results were reported from clinical studies using new anti-lymphoma drugs such as rituximab, iibritumomab, or purine analogs (cladribine and fludarabine), and auto-HSCT with effectively purged stem cells or allogeneic HSCT.
  • These therapeutic strategies hold a possibility of cure for indolent lymphomas.
  • Antibiotic treatment for Helicobacter pylori-positive localized gastric MALT lymphoma is the state of the art therapy.
  • However, there is no standard therapy for advanced stage MALT lymphoma.
  • Risk adapted therapy using the International Prognostic Index is essential for the treatment of aggressive NHL.
  • Three courses of CHOP followed by IFRT for localized aggressive NHL and 8 courses of CHOP for the low-risk group of advanced stage aggressive NHL are the state of the art therapies, respectively.
  • High-dose chemotherapy with auto-HSCT is also the state of the art for sensitive relapse patients with aggressive NHL.
  • Although some clinical studies suggested that high-dose chemotherapy with auto-HSCT as up-front setting for high-intermediate or high-risk group aggressive NHL is more effective than conventional chemotherapy, the efficacy remains to be determined.
  • The development of new therapeutic strategies with combined use of molecular targeting drugs such as rituximab, or new anti-lymphoma drugs such as purine analogs, and HSCT is desired for more effective therapy for refractory lymphomas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / therapy. Lymphoma / therapy
  • [MeSH-minor] Clinical Trials as Topic. Helicobacter Infections / drug therapy. Helicobacter pylori. Hematopoietic Stem Cell Transplantation. Humans. Leukemia, Lymphoid / therapy. Lymphoma, B-Cell, Marginal Zone / drug therapy. Lymphoma, B-Cell, Marginal Zone / microbiology. Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, Non-Hodgkin / therapy. Prognosis. Radioimmunotherapy. Recurrence

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11579632.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 77
  •  go-up   go-down


11. Ono M, Kobayashi Y, Shibata T, Maruyama D, Kim SW, Watanabe T, Mikami Y, Tobinai K: Nocardia exalbida brain abscess in a patient with follicular lymphoma. Int J Hematol; 2008 Jul;88(1):95-100
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nocardia exalbida brain abscess in a patient with follicular lymphoma.
  • We present the first report of N. exalbida brain abscess in a 63-year-old male patient with follicular lymphoma.
  • He developed abnormal neurological findings during follicular lymphoma treatment, brain CT revealed ring-enhancing, multiloculated lesions, and N. exalbida was detected by aspiration of the lesion.
  • It should be noted that such an infection can occur in patients treated with conventional chemotherapy against malignant lymphoma.
  • [MeSH-major] Anti-Bacterial Agents / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Brain Abscess / drug therapy. Lymphoma, Follicular / drug therapy. Nocardia. Nocardia Infections / drug therapy

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • MedlinePlus Health Information. consumer health - Antibiotics.
  • National BioResource Project. culture/stock collections - NBRP resources .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Bone Marrow Transplant. 1997 Sep;20(5):425-6 [9339761.001]
  • [Cites] J Infect Dis. 1976 Sep;134(3):286-9 [789786.001]
  • [Cites] Blood. 1994 May 15;83(10):2906-11 [7910051.001]
  • [Cites] J Antimicrob Chemother. 1992 Feb;29(2):169-72 [1506332.001]
  • [Cites] Clin Microbiol Rev. 1994 Jul;7(3):357-417 [7923055.001]
  • [Cites] Arch Intern Med. 1983 Apr;143(4):711-8 [6340623.001]
  • [Cites] Medicine (Baltimore). 2004 Sep;83(5):300-13 [15342974.001]
  • [Cites] Medicine (Baltimore). 1974 Sep;53(5):391-401 [4604319.001]
  • [Cites] Clin Infect Dis. 1996 Nov;23(5):1012-9 [8922795.001]
  • [Cites] J Clin Neurosci. 2006 May;13(4):481-5 [16678731.001]
  • [Cites] J Med Microbiol. 2005 Nov;54(Pt 11):1107-10 [16192444.001]
  • [Cites] Int J Hematol. 2007 Dec;86(5):455-8 [18192116.001]
  • [Cites] Kansenshogaku Zasshi. 2006 Nov;80(6):721-5 [17176862.001]
  • [Cites] Int J Syst Evol Microbiol. 2006 Jun;56(Pt 6):1193-6 [16738090.001]
  • [Cites] Int Ophthalmol. 2007 Oct;27(5):333-6 [17476571.001]
  • [Cites] Clin Microbiol Rev. 1994 Apr;7(2):213-64 [8055469.001]
  • [Cites] Drugs. 1995 Jul;50(1):73-101 [7588092.001]
  • [Cites] Neurosurgery. 1994 Oct;35(4):622-31 [7808604.001]
  • [Cites] Clin Infect Dis. 1996 Jun;22(6):891-903; quiz 904-5 [8783685.001]
  • [Cites] J Clin Microbiol. 2005 Sep;43(9):4895-7 [16145170.001]
  • [Cites] Int J Med Microbiol. 2002 Sep;292(3-4):277-82 [12398218.001]
  • [Cites] Eur J Epidemiol. 2004;19(4):383-9 [15180109.001]
  • [Cites] Transplant Proc. 2006 Nov;38(9):3121-4 [17112915.001]
  • [Cites] Clin Infect Dis. 1997 Jun;24(6):1154-60 [9195074.001]
  • (PMID = 18498026.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


12. Kataoka T, Ishida Y, Kurokawa R, Takeshita S, Ohta K, Nishimura Y, Yokoyama M: [A case of malignant lymphoma associated with diffuse pulmonary involvement successfully treated with rituximab]. Nihon Kokyuki Gakkai Zasshi; 2003 Dec;41(12):899-904
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of malignant lymphoma associated with diffuse pulmonary involvement successfully treated with rituximab].
  • A 66-year-old man was admitted to our hospital with a chief complaint of fever.
  • Histopathological examination of the inguinal lymph nodes revealed follicular B-cell non-Hodgkin's lymphoma (NHL).
  • In spite of 9 cycles of chemotherapy (CHOP/COP), progression of the disease was seen.
  • Fever and dyspnea developed.
  • The chest radiograph revealed diffuse pulmonary infiltrates.
  • Transbronchial biopsy revealed pulmonary involvement of diffuse B-cell lymphoma.
  • Salvage chemotherapy (ESHAP, EPOCH) was not effective.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Lung Neoplasms / drug therapy. Lymphoma, B-Cell / drug therapy. Lymphoma, Follicular / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14727553.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


13. Robinson SN, Freedman AS, Neuberg DS, Nadler LM, Mauch PM: Loss of marrow reserve from dose-intensified chemotherapy results in impaired hematopoietic reconstitution after autologous transplantation: CD34(+), CD34(+)38(-), and week-6 CAFC assays predict poor engraftment. Exp Hematol; 2000 Dec;28(12):1325-33
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of marrow reserve from dose-intensified chemotherapy results in impaired hematopoietic reconstitution after autologous transplantation: CD34(+), CD34(+)38(-), and week-6 CAFC assays predict poor engraftment.
  • Autologous hematopoietic stem cell transplantation (HSCT) is an increasingly successful modality for treating a variety of malignant disorders in the clinic.
  • To further investigate the ability to predict for impaired hematopoiesis, we measured different stem/progenitor cell populations transplanted and time to engraftment.
  • Patients with previously untreated, advanced-stage follicular lymphoma were treated in sequential prospective protocols with 6-8 cycles of standard-dose (SD) cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), or four cycles of a higher-dose (HD) CHOP and granulocyte colony-stimulating factor, to induce remission prior to high-dose cyclophosphamide, total body irradiation, and autologous bone marrow transplantation (ABMT).
  • Cryopreserved marrow samples obtained prior to ABMT were assayed for CD34(+), CD34(+)38(-), and cobblestone area-forming cell (CAFC) frequencies.
  • Time to platelet engraftment was plotted against progenitor/stem cell numbers transplanted for each patient and threshold values were developed for all three stem/progenitor cell populations.
  • Approximately 50% of patients received marrow progenitor/stem cell numbers above the threshold values and all engrafted without delay.
  • However, transplantation of stem/progenitor cell numbers below threshold values did not uniformly predict for delayed platelet engraftment.
  • These data suggest the presence of a crucial stem cell population not represented by the stem/progenitor cell populations studied in these experiments.
  • [MeSH-major] Antigens, CD. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Bone Marrow Cells / pathology. Hematopoiesis / drug effects. Hematopoietic Stem Cell Transplantation. Transplantation, Autologous
  • [MeSH-minor] ADP-ribosyl Cyclase. Adult. Antigens, CD34 / analysis. Antigens, CD38. Antigens, Differentiation / analysis. Cell Count. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Female. Graft Survival. Hematopoietic Stem Cells / immunology. Hematopoietic Stem Cells / pathology. Humans. Immunophenotyping. Lymphoma, Follicular / drug therapy. Lymphoma, Follicular / pathology. Lymphoma, Follicular / surgery. Male. Membrane Glycoproteins. Middle Aged. NAD+ Nucleosidase / analysis. Prednisone / administration & dosage. Prednisone / adverse effects. Vincristine / administration & dosage. Vincristine / adverse effects

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11146154.001).
  • [ISSN] 0301-472X
  • [Journal-full-title] Experimental hematology
  • [ISO-abbreviation] Exp. Hematol.
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / P50 HL 54785-01; United States / NCI NIH HHS / CA / R01 CA 10941-26
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] NETHERLANDS
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD34; 0 / Antigens, Differentiation; 0 / Membrane Glycoproteins; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 3.2.2.5 / ADP-ribosyl Cyclase; EC 3.2.2.5 / Antigens, CD38; EC 3.2.2.5 / CD38 protein, human; EC 3.2.2.5 / NAD+ Nucleosidase; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


14. Straus DJ: Gallium nitrate in the treatment of lymphoma. Semin Oncol; 2003 Apr;30(2 Suppl 5):25-33
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gallium nitrate in the treatment of lymphoma.
  • Gallium nitrate is effective and well tolerated for the treatment of cancer-related hypercalcemia.
  • Radioactive gallium ((67)Ga) is concentrated at sites of malignant lymphoma, Hodgkin's disease, and other tumors.
  • Gallium nitrate has substantial single-agent activity in the treatment of patients with advanced lymphoma and has also shown activity when used in combination with other agents.
  • Significant response rates have been observed in patients with diffuse large cell lymphoma, small lymphocytic lymphoma, and follicular lymphoma.
  • Because of its unique mechanism of action, gallium nitrate could be non-cross-resistant with many of the cytotoxic agents used as standard chemotherapy for non-Hodgkin's lymphoma.
  • Nephrotoxicity, the most frequent adverse event associated with gallium nitrate, can generally be minimized by ensuring adequate oral hydration and avoiding concomitant use of other nephrotoxic drugs.
  • Gallium nitrate causes little myelosuppression and is therefore well tolerated by patients with advanced disease who have received extensive prior therapy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Gallium / therapeutic use. Lymphoma / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GALLIUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Elsevier Inc. All rights reserved.
  • (PMID = 12776257.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 13494-90-1 / gallium nitrate; CH46OC8YV4 / Gallium
  • [Number-of-references] 32
  •  go-up   go-down


15. Friedberg JW, Fisher RI: Iodine-131 tositumomab (Bexxar): radioimmunoconjugate therapy for indolent and transformed B-cell non-Hodgkin's lymphoma. Expert Rev Anticancer Ther; 2004 Feb;4(1):18-26
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Iodine-131 tositumomab (Bexxar): radioimmunoconjugate therapy for indolent and transformed B-cell non-Hodgkin's lymphoma.
  • Tositumomab is an immunoglobulin G murine monoclonal antibody that binds to the CD20 antigen on the surface of normal and malignant human B-cells.
  • The iodine-131 tositumomab regimen was approved by the US Food and Drug Administration in June 2003 for the treatment of patients with CD20-positive, follicular non-Hodgkin's lymphoma, both with and without transformation, whose disease is refractory to rituximab (Rituxan) and has relapsed following chemotherapy.
  • Unlike chemotherapy, the majority of nonhematologic adverse events associated with iodine-131 tositumomab are mild to moderate in nature and usually self limited.
  • Iodine-131 tositumomab represents one of the most active single agents for the treatment of recurrent indolent and transformed B-cell non-Hodgkin's lymphoma, as demonstrated by several clinical trials summarized in this review.
  • At the present time, the use of radioimmunoconjugate therapy is largely limited to patients with disease refractory to rituximab therapy and transformed disease not amenable to high-dose therapy and autologous stem cell support.
  • Longer follow-up of ongoing clinical trials should provide reassurance as to safety and insights as to the additive stem cell toxicity from iodine-131 tositumomab administration.
  • Studies are also addressing the role of iodine-131 tositumomab as a component of initial therapy for indolent non-Hodgkin's lymphoma and in additional histologies of non-Hodgkin's lymphoma.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antigens, CD20 / immunology. Antineoplastic Agents / therapeutic use. Immunoconjugates / therapeutic use. Lymphoma, B-Cell / drug therapy. Radioimmunotherapy
  • [MeSH-minor] Clinical Trials as Topic. Humans. Iodine Radioisotopes / therapeutic use. Neoplasm Recurrence, Local / drug therapy

  • Genetic Alliance. consumer health - Indolent B cell lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright Future Drugs Ltd.
  • (PMID = 14748653.001).
  • [ISSN] 1473-7140
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA102216-01
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD20; 0 / Antineoplastic Agents; 0 / Immunoconjugates; 0 / Iodine Radioisotopes; 0 / iodine-131 anti-B1 antibody
  • [Number-of-references] 67
  •  go-up   go-down


16. Ohno H, Ishikawa T, Kitajima H, Nomura S, Suzuki T, Konishi H, Ohno Y, Onishi R, Konaka Y, Arima N, Doi S, Nasu K, Takahashi T, Tsudo M, Fukuhara S, Uchiyama T: [Significance of soluble interleukin-2 receptor alpha chain in the management of patients with malignant lymphoma: a multi-center study]. Rinsho Ketsueki; 2002 Mar;43(3):170-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Significance of soluble interleukin-2 receptor alpha chain in the management of patients with malignant lymphoma: a multi-center study].
  • A multi-center series of 117 patients with malignant lymphoma were analyzed to evaluate the clinical significance of soluble interleukin-2 receptor alpha chain (sIL-2R alpha).
  • The initial levels of sIL-2R alpha ranged from 277 U/ml to 22,800 U/ml with a mean level of 3,451 +/- 4,268 U/ml and a median level of 1,600 U/ml.
  • The sIL-2R alpha levels of the diffuse lymphoma/intermediate-grade subtypes defined by the LSG classification/Working Formulation were higher than those of the follicular lymphoma/low-grade subtypes.
  • There was a tendency for B-cell lymphomas to show higher sIL-2R alpha levels than T-cell lymphomas.
  • This study confirmed that sIL-2R alpha is a convenient and useful marker in the management of malignant lymphoma.
  • [MeSH-major] Lymphoma, Non-Hodgkin / drug therapy. Receptors, Interleukin-2 / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11979748.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Multicenter Study
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Receptors, Interleukin-2
  •  go-up   go-down


17. Rizzi R, Liso A, Pannunzio A, Carluccio P, Specchia G, Liso V: Concomitant primary polycythemia vera and follicle center cell non-Hodgkin lymphoma: a case report and review of the literature. Leuk Lymphoma; 2002 Nov;43(11):2217-20
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concomitant primary polycythemia vera and follicle center cell non-Hodgkin lymphoma: a case report and review of the literature.
  • The association of myeloproliferative and lymphoproliferative disorders is well known after cytotoxic drug or radiation exposure, while it is remarkably rare prior to therapy.
  • We report on a patient simultaneously diagnosed as having polycythemia vera and II3A follicle center cell non-Hodgkin lymphoma (grade 1).
  • At this timepoint, he is on 12-year follow-up, characterized by post-polycythemia myeloid metaplasia with myelofibrosis and persistent complete remission of lymphoma.
  • To the best of our knowledge based on a computer-aided review of the literature (MED-LINE 1966-2002), this is the sixth case of concomitant primary polycythemia vera and lymphoma of non-Hodgkin type.
  • Besides, there is a single literature report on polycythemia vera coexisting with the Hodgkin's lymphoma.
  • In our case as well as in the recorded ones, two independent malignant clones of myeloid and lymphoid origin, respectively, seem to have arisen.
  • [MeSH-major] Lymphoma, Follicular / pathology. Polycythemia Vera / pathology
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Clone Cells / pathology. Humans. Male. Neoplasms, Second Primary / pathology. Remission Induction


18. Ogura M: [Progress in therapeutic strategy for malignant lymphoma]. Gan To Kagaku Ryoho; 2005 Mar;32(3):309-27
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Progress in therapeutic strategy for malignant lymphoma].
  • Dramatic progress in therapeutic strategy for malignant lymphoma has been made during recent few years because of the development of new drugs or new therapeutic modalities such as rituximab, purine analogue, purged autologous PBSCT or allogeneic PBSCT by the reduced intensity technique.
  • Rituximab in particular changed the golden standard therapy for previously untreated patients with diffuse large B-cell lymphoma from CHOP therapy to rituximab-CHOP (R-CHOP) therapy in all risk groups.
  • In follicular lymphoma with no treatment strategies associated with curative potential and median survival in the range of 8 to 13 years, prolonged progression-free survival has been reported by maintenance-use of rituximab, R-CHOP therapy, purine analog, in vivo purged auto-PBSCT by rituximab, or reduced intensity stem-cell transplantation (RIST), although no curable survival benefit has yet been demonstrated by any strategies.
  • Short courses (4 courses) of ABVD followed by involved field irradiation therapy (IFRT) for localized early-stage Hodgkin lymphoma (HL), and full courses (6-8 courses) of ABVD (d) for advanced stage HL are the golden standard therapy for HL, respectively.
  • Clinical trials of new therapies with more efficacy and less toxicity have been undertaken.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation. Hodgkin Disease / therapy. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Algorithms. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Clinical Trials as Topic. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Dose-Response Relationship, Drug. Doxorubicin / administration & dosage. Humans. Neoplasm Staging. Prednisone / administration & dosage. Rituximab. Salvage Therapy. Vinblastine / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15791814.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  • [Number-of-references] 71
  •  go-up   go-down


19. Derringer GA, Thompson LD, Frommelt RA, Bijwaard KE, Heffess CS, Abbondanzo SL: Malignant lymphoma of the thyroid gland: a clinicopathologic study of 108 cases. Am J Surg Pathol; 2000 May;24(5):623-39
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant lymphoma of the thyroid gland: a clinicopathologic study of 108 cases.
  • All patients presented with a thyroid mass.
  • The PTLs were classified as marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) or MZBL (n = 30), diffuse large B-cell lymphoma (DLBCL) with MZBL (n = 36), DLBCL without MZBL (n = 41), and follicle center lymphoma (FCL; n = 1).
  • Excluding the FCL, features of lymphomas of MALT-type were identified in all groups, despite a follicular architecture in 23% of cases.
  • Ninety-one percent of patients presented with stage IE or IIE disease, whereas 69% had perithyroidal soft tissue infiltration.
  • All patients were treated with surgical excision followed by adjuvant therapy (76%): chemotherapy (15%), radiation (19%), or a combination of radiation and chemotherapy (42%).
  • Statistically, stages greater than IE, presence of DLBCL, rapid clinical growth, abundant apoptosis, presence of vascular invasion, high mitotic rate, and infiltration of the perithyroidal soft tissue were significantly associated with death with disease.
  • In summary, PTLs typically occur in middle- to older-aged individuals as a thyroid mass, with a predilection for females.
  • Despite their histologic heterogeneity and frequent simulation of other lymphoma subtypes, virtually all PTLs are lymphomas of MALT-type arising in the setting of LT.
  • Overall, PTLs have a favorable outcome with appropriate therapy, but prognosis depends on both clinical stage and histology.
  • MZBL and stage IE tumors have an excellent prognosis, whereas tumors with a large cell component or DLBCL or stage greater than IE have the greatest potential for a poor outcome.
  • [MeSH-major] Lymphoma / pathology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Female. Humans. Lymph Node Excision. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, Follicular / pathology. Male. Middle Aged. Neoplasm Staging. Treatment Outcome

  • Genetic Alliance. consumer health - Thyroid Lymphoma.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10800981.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


20. Nascimento AF, Winters GL, Pinkus GS: Primary cardiac lymphoma: clinical, histologic, immunophenotypic, and genotypic features of 5 cases of a rare disorder. Am J Surg Pathol; 2007 Sep;31(9):1344-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cardiac lymphoma: clinical, histologic, immunophenotypic, and genotypic features of 5 cases of a rare disorder.
  • Modern imaging technology now permits early diagnosis and treatment.
  • This report describes the clinical, histologic, immunophenotypic, and molecular genetic findings for 5 patients with malignant lymphoma restricted to the cardiac muscle, with or without pericardial involvement.
  • All tumors were of B-cell phenotype and included 4 cases of large cell lymphoma and one unclassifiable small cell lymphoma.
  • In 2 cases, a follicular center cell origin was supported by reactivity of the neoplastic cells for CD10 and bcl-6 and by bcl-2 gene rearrangement by molecular analysis.
  • Two patients are alive without disease after chemotherapy with CHOP after 120 and 192 months.
  • One patient underwent chemotherapy with CHOP and rituximab, and shows persistent cardiac involvement by lymphoma but with a decrease in tumor burden at 7 months of follow-up.
  • Clinical outcome is variable; however, early diagnosis in conjunction with effective treatment (surgery and/or chemotherapy) may result in an excellent prognosis.
  • Primary cardiac lymphoma should be included in the differential diagnosis of a right atrial mass.
  • [MeSH-major] Antigens, CD / analysis. Gene Expression Regulation, Neoplastic. Heart Neoplasms / diagnosis. Lymphoma, B-Cell / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / administration & dosage. Cyclophosphamide / therapeutic use. Diagnosis, Differential. Doxorubicin / administration & dosage. Doxorubicin / therapeutic use. Female. Gene Rearrangement. Genotype. Heart Atria / pathology. Heart Ventricles / pathology. Humans. Immunophenotyping. Karyotyping. Middle Aged. Pericardium / pathology. Prednisone / administration & dosage. Prednisone / therapeutic use. Treatment Outcome. Vincristine / administration & dosage. Vincristine / therapeutic use

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17721189.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


21. Das DK: Serous effusions in malignant lymphomas: a review. Diagn Cytopathol; 2006 May;34(5):335-47
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serous effusions in malignant lymphomas: a review.
  • Although the frequency of pleural effusion is 20-30% in non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD), the involvement of peritoneal and pericardial cavities is uncommon.
  • Among lymphoma subtypes, T-cell neoplasms, especially the lymphoblastic lymphomas, more frequently involve the serous fluids.
  • Cytologic features of specific lymphoma subtypes such as lymphoblastic lymphoma, follicular center cell lymphoma, including Burkitt-type lymphoma, marginal zone lymphoma, MALT lymphoma, and anaplastic large-cell lymphoma, etc., have been described in the literature.
  • The differential diagnostic problems of lymphomas in serous effusions include reactive lymphocytoses, early involvement by lymphomatous process, small round-cell tumors (SRCT), and presence of look-alike of Reed-Sternberg cells.
  • ICC not only distinguishes lymphomas from reactive lymphocytoses and SRCTs, it significantly modifies the morphologic diagnosis to achieve a better classification of lymphomas.
  • Morphometry also distinguishes reactive lymphocytoses from malignant lymphoma with a high degree of sensitivity (>85%) and specificity (>95%).
  • This body cavity based lymphoma (BCBL) is a distinct clinicopathologic entity and is found predominantly in AIDS patients with preexisting Kaposi sarcoma.
  • Cytomorphologically, PEL is usually a large-cell lymphoma, which appears to bridge features of large-cell immunoblastic and anaplastic large-cell lymphoma (ALCL).
  • Most of these cases comprise a unique subgroup of B-cell lymphoma, with features of both high-grade anaplastic and B-immunoblastic lymphoma, but T-cell and/or natural killer cell immunophenotypes are described.
  • The presence of pleural effusion at the time of presentation is not only associated with extremely poor outcome of lymphomas, it is also a predictor of disease relapse after chemotherapy and decreased survival.
  • When the patients of lymphomatous pleural effusions with and without mediastinal mass present in respiratory distress, thoracocentesis is the initial diagnostic and therapeutic choice in these patients.
  • In such situations, cytology along with ancillary studies not only gives a quick diagnosis of lymphoma, but also offers prognostically significant information such as classification of lymphomas, its grade and immunophenotype, and presence/absence of viral DNAs and tumor lysis syndrome.
  • [MeSH-major] Cytodiagnosis / methods. Lymphoma / complications. Pleural Effusion, Malignant / etiology
  • [MeSH-minor] Ascitic Fluid / pathology. Carcinoma, Small Cell / pathology. Diagnosis, Differential. Female. Hodgkin Disease / pathology. Humans. Immunophenotyping. Lymphocytosis / pathology. Male. Pericardial Effusion / etiology. Pericardial Effusion / pathology. Reed-Sternberg Cells / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16604559.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 136
  •  go-up   go-down


22. Rao AV, Schmader K: Monoclonal antibodies as targeted therapy in hematologic malignancies in older adults. Am J Geriatr Pharmacother; 2007 Sep;5(3):247-62
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Monoclonal antibodies as targeted therapy in hematologic malignancies in older adults.
  • BACKGROUND: Biological agents are proving to be increasingly useful and exciting additions to the antineoplastic armamentarium, but many clinicians are unfamiliar with the properties of these types of agents.
  • OBJECTIVES: This review focuses on monoclonal antibodies (MAbs) that are used in the treatment of hematologic malignancies.
  • Our goal was to provide the reader with information on trials that led to US Food and Drug Administration (FDA) approval of commonly used MAbs in hematologic malignancies, including their mechanisms of action and pharmacokinetics, with specific emphasis on use in elderly patients; we also present data on toxicities and precautions to be aware of when administering these drugs.
  • RESULTS: Alemtuzumab is a recombinant DNA-derived, humanized MAb directed against the CD52 B-cell antigen.
  • It is indicated for the treatment of B-cell chronic lymphocytic leukemia (CLL) in patients who have been treated with alkylating agents and who have failed to respond to fludarabine therapy.
  • Gemtuzumab ozogamicin is an MAb conjugated with a cytotoxic antitumor antibiotic, calicheamicin.
  • It has been approved for use in patients with CD33-positive acute myeloid leukemia (AML) in first relapse who are aged > or =60 years and who are not considered candidates for other cytotoxic chemotherapy.
  • Rituximab, one of the first MAbs approved by the FDA for use in human cancers, is an antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes.
  • It is extensively used in the treatment of B-cell malignancies, such as CLL, and non-Hodgkin's lymphomas (NHLs), such as follicular lymphoma and diffuse large B-cell lymphoma.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Agents / administration & dosage. Drug Delivery Systems. Hematologic Neoplasms / drug therapy

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17996665.001).
  • [ISSN] 1543-5946
  • [Journal-full-title] The American journal of geriatric pharmacotherapy
  • [ISO-abbreviation] Am J Geriatr Pharmacother
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 0 / gemtuzumab; 3A189DH42V / alemtuzumab; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 62
  •  go-up   go-down


23. Kim JA: Targeted therapies for the treatment of cancer. Am J Surg; 2003 Sep;186(3):264-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeted therapies for the treatment of cancer.
  • BACKGROUND: In contrast to conventional cytotoxic chemotherapy and radiation therapy, a new method of targeted cancer therapeutics is being directed towards molecular pathways that underlie the malignant phenotype.
  • These therapies target specific tumor cell receptors or signaling events that are critical to tumor progression while reducing toxicity to normal cells.
  • DATA SOURCES: The purpose of this review is to highlight several examples of novel targeted therapeutics that are currently approved by the FDA for treatment of patients with cancer.
  • Rituxan is a humanized monoclonal antibody that binds to the CD20 antigen present on B cell lymphomas and is currently approved for the treatment of patients with relapsed or refractory low-grade CD20 positive follicular lymphoma.
  • Finally, Gleevec is a tyrosine kinase inhibitor that inhibits abl-specific phosphorylation and is approved for use in select patients with chronic myelogenous leukemia that is refractory to interferon therapy.
  • CONCLUSIONS: The lessons learned from the use of these therapeutics will add to the growing knowledge of mechanistic approaches to the treatment of patients with cancer based upon targeted therapies, and herald a bright future that will improve the lives of patients with cancer.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Neoplasms / therapy
  • [MeSH-minor] Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Antibodies, Monoclonal, Murine-Derived. Benzamides. Breast Neoplasms / drug therapy. Female. Humans. Imatinib Mesylate. Lymphoma, B-Cell / drug therapy. Male. Piperazines / therapeutic use. Protein-Tyrosine Kinases / antagonists & inhibitors. Pyrimidines / therapeutic use. Rituximab. Trastuzumab

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. Trastuzumab .
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12946830.001).
  • [ISSN] 0002-9610
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 4F4X42SYQ6 / Rituximab; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases; P188ANX8CK / Trastuzumab
  • [Number-of-references] 32
  •  go-up   go-down






Advertisement